Lexicon data for sotagliflozin at American Diabetes Assn

 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of clinical data for sotagliflozin will be presented at the upcoming 79^th American Diabetes Association (ADA) Scientific Sessions in San Francisco, California. The five accepted posters reflect Lexicon and its collaborator, Sanofi’s efforts to address the unmet need and potential treatment options for the management of type 1 diabetes.

ePosters

• Saturday, June 8, 11:30am, Exhibit Hall (ePoster Theater B); ePoster Session “The Latest on SGLT Inhibition”
  • Sotagliflozin Reduces Glucose Variability and Risk for Hyperglycemia in Adults with Type 1 Diabetes (1191-P)
  • The Impact of Sotagliflozin on Renal Function, Albuminuria and Blood Pressure in Adults with Type 1 Diabetes (1196-P)

Posters

• Sunday, June 9, 12:00pm, General Poster Session, Poster Hall (Hall F, North, Exhibition Level)
  • Sotagliflozin Reduces Markers of Arterial Stiffness in T1D:  Pooled Analysis from InTandem1 and InTandem2 Clinical Trials (1212-P)
  • Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D (1220-P)
  • Burden of Cardiovascular Comorbidity in US Adults with T1D (168-LB)
  • ePosters listed above also presented during this session

About Sotagliflozin

Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an investigational oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney.

Zynquista™ (sotagliflozin) has been approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index ≥ 27 kg/m², who could not achieve adequate glycemic control despite optimal insulin therapy. Sotagliflozin has not yet been approved for use in any other jurisdiction.

https://www.globenewswire.com/news-release/2019/06/04/1863811/0/en/Lexicon-Pharmaceuticals-to-Present-New-Clinical-Data-at-79th-American-Diabetes-Association-Scientific-Sessions.html